Shah Lab

To compare the risk of post hospital discharge mortality between patients with an exposure to assisted thoracoscopic surgery versus open resection.

1. Treatment Cohort - Patients with known or suspected lung cancer on assisted thoracoscopic surgery.
2. Comparator Cohort - Patients with known or suspected lung cancer on open resection.
3. Outcome - Mortality after 30, 60 and 90 days after discharge from hospital.
4. Risk Window - 30, 60 and 90 days after discharge from hospital upto 3 years.

Question - 2 To compare the risk of developing opioid addiction in patients with opioid prescription. Treatment Cohort - Patients prescribed an opioid (hydrocodone, oxycodone, morphine and codeine) who developed addiction in the following one year. Comparator Cohort - Patients prescribed an opioid (hydrocodone, oxycodone, morphine and codeine) who did not developed opioid addiction. Outcome - Development of opioid addiction. Risk Window - One year from the time of first opioid prescription.

Question - 3 To compare the risk of amputation between diabetic patients treated with canagliflozin versus diabetic patients treated with other diabetic drugs. Treatment Cohort - Diabetic patients treated with canagliflozin. Outcome Cohort - Diabetic patients treated with other diabetic drugs or other forms of SGLT-2 inhibitors. Outcome - Amputation after treatment. Risk Window - 1 day after treatment exposure or 0 days after exposure end to end of patient timeline.

Question - 4 To compare the risk of mortality between patients with bladder cancer treated with aspirin for one year versus patients with bladder cancer not treated with aspirin. Treatment Cohort - Patients with bladder cancer treated with aspirin at least for one year . Comparator Cohort - Patients with bladder cancer not treated with aspirin. Outcome - Mortality after treatment. Risk Window - 1 day after treatment exposure upto 5 years after treatment exposure end.

Question - 5 To compare the risk of mortality between patients with heart disease treated with clarithromycin versus patients with heart disease treated with amoxicillin. Treatment Cohort - Patients with heart disease treated with clarithromycin. Comparator Cohort - Patients with heart disease treated with amoxicillin. Outcome - Mortality. Risk Window - 6 Years after treatment exposure.

Question - 6 To compare the risk of opportunistic infections between patients with anaplastic large cell lymphoma (ALCL) or Hodgkin lymphoma (HL) treated with CD30 inhibitors versus patients with ALCL or HL treated with antineoplastics or immunomodulators. Treatment Cohort - Patient with ALCL or HL treated with brentuximab. Comparator Cohort - Patients with ALCL or HL treated with either antineoplastics or immunomodulators, or both. Outcome - Diagnosis of opportunistic infections. Risk Window - 1 day after treatment exposure start to 90 days after treatment exposure end.

Question - 7 To compare the risk of mortality between patients with asthma treated with inhaled long-acting muscarinic antagonists (LAMA) without concomitant use of inhaled corticosteroids (IC) versus patients with asthma treated with LAMA and IC. Treatment Cohort - Patients with asthma treated with LAMA or LAMA and long-acting beta2-agonists (LABA) or leukotriene receptor antagonists (LTRA). Comparator Cohort - Patients with asthma treated with LAMA and IC as combination of either LAMA and IC only or LAMA and IC and LABA or LTRA. Outcome - All cause mortality as primary outcome and asthma-related mortality as secondary outcome. Risk Window - 1st day of treatment exposure to end of study.

Question - 8 To compare the risk of serious cardiovascular events (sudden cardiac death, acute myocardial infarction and stroke) between the new users of triptans versus patients who used triptans for one year (short term) and more than one year (long term). Treatment Cohort - New users treated with triptans. Comparator Cohort - Patients treated with triptans for one year (short-term) and patients treated with triptans for more than one year (long term). Outcome - Sudden cardiac death, acute myocardial infarction and stroke after exposure. Risk Window - 1 day after treatment exposure start to 0 day after treatment exposure ends.

More discussion on these question can be seen here at OHDSI Forum